Cellular immunity plays a major role in the control of HSV-1 infection/reactivation with a potential impact on the clinical-therapeutic management of immunocompromised patients, such as transplant recipients. Herein, we quantitatively evaluated T-cell response directed at HSV-1 by a newly developed IFN-γ EliSPOT assay in 53 patients (including 45 lung transplant recipients and eight subjects in waiting list). Overall, 62.2% of transplant patients and 62.5% of subjects on the waiting list showed a response to HSV-1 with no significant difference in the level of virus-specific cellular immunity. Response tended to be lower in the first three months posttransplantation with a progressive recovery of pretransplantation status by the second year and in the presence of HSV-1 DNA positivity in bronchoalveolar lavage. As expected, no response was found in seronegative patients. No significant difference in the level of response according to IgM and IgG status was found. Further studies are required to define the role of HSV-1 specific immune response for the clinical-therapeutic management of lung transplant patients and in other clinical settings and to define cut-off levels discriminating between absence/low and strong response to be related to the risk of viral infection/reactivation.

Development of an EliSPOT assay for HSV-1 and clinical validation in lung transplant patients

Costa, Cristina;Rittà, Massimo;Sinesi, Franca;Bianco, Gabriele;Sidoti, Francesca;Solidoro, Paolo;Cavallo, Rossana
2017

Abstract

Cellular immunity plays a major role in the control of HSV-1 infection/reactivation with a potential impact on the clinical-therapeutic management of immunocompromised patients, such as transplant recipients. Herein, we quantitatively evaluated T-cell response directed at HSV-1 by a newly developed IFN-γ EliSPOT assay in 53 patients (including 45 lung transplant recipients and eight subjects in waiting list). Overall, 62.2% of transplant patients and 62.5% of subjects on the waiting list showed a response to HSV-1 with no significant difference in the level of virus-specific cellular immunity. Response tended to be lower in the first three months posttransplantation with a progressive recovery of pretransplantation status by the second year and in the presence of HSV-1 DNA positivity in bronchoalveolar lavage. As expected, no response was found in seronegative patients. No significant difference in the level of response according to IgM and IgG status was found. Further studies are required to define the role of HSV-1 specific immune response for the clinical-therapeutic management of lung transplant patients and in other clinical settings and to define cut-off levels discriminating between absence/low and strong response to be related to the risk of viral infection/reactivation.
NEW MICROBIOLOGICA
40
4
251
257
Cellular immune response; EliSPOT assay; Herpes simplex virus type 1; Lung transplantation; Adult; Enzyme-Linked Immunospot Assay; Female; Herpes Simplex; Herpesvirus 1, Human; Humans; Lung Transplantation; Male; Middle Aged; T-Lymphocytes; Transplant Recipients; Virus Activation; Young Adult; Immunity, Cellular
Costa, Cristina; Di Nauta, Alessia; Rittà, Massimo; Sinesi, Franca; Bianco, Gabriele; Sidoti, Francesca; Solidoro, Paolo; Cavallo, Rossana
File in questo prodotto:
File Dimensione Formato  
Costa_New_Microbiol.pdf

accesso aperto

Tipo di file: PREPRINT (PRIMA BOZZA)
Dimensione 321.87 kB
Formato Adobe PDF
321.87 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1680861
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact